Detalhe da pesquisa
1.
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
N Engl J Med
; 389(9): 783-794, 2023 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646676
2.
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX).
Blood
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452197
3.
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
Lancet
; 401(10386): 1427-1437, 2023 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37003287
4.
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol
; 10(5): e322-e332, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37003278
5.
Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP array.
Haematologica
; 97(2): 304-9, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21993689
6.
Clinical Analysis of Hospitalized Patients with Hemophilia A: Single-hemophilia Treatment Center Experience in Korea over 10 years.
Blood Res
; 56(3): 141-149, 2021 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34349040
7.
Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients.
J Thromb Haemost
; 19(4): 967-975, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33540485
8.
Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.
J Thromb Haemost
; 18 Suppl 1: 5-14, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32544297
9.
The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A.
Blood Res
; 54(3): 204-209, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730688
10.
Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.
Blood Res
; 54(3): 198-203, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730687
11.
A Combined Ultrasonographic and Conventional Radiographic Assessment of Hemophilic Arthropathy.
Indian J Hematol Blood Transfus
; 33(3): 380-388, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28824241
12.
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Thromb Haemost
; 117(2): 252-261, 2017 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27904904
13.
A pediatric case of idiopathic Harlequin syndrome.
Korean J Pediatr
; 59(Suppl 1): S125-S128, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28018464
14.
Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.
Korean J Pediatr
; 56(7): 291-7, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23908669
15.
Mutation analysis of factor VIII in Korean patients with severe hemophilia A.
Int J Hematol
; 91(5): 784-91, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20533009
16.
Effects of thyroxine on hyperkalemia and renal cortical Na+, K+ - ATPase activity induced by cyclosporin A.
J Korean Med Sci
; 17(5): 625-32, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12378013